Parametritis

Summary

Parametritis (MONDO:0006887) is a disease. A subtype of pelvic inflammatory disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	parametritis
Mondo ID	MONDO:0006887
EFO	EFO:1001084
MeSH	D010249
DOID	DOID:1260
SNOMED CT	280483007
UMLS	C0030455
MedGen	18295
Is cancer (heuristic)	no

Also known as: inflammation of parametrium · parametrium inflammation

Disease family

This is a subtype of pelvic inflammatory disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › pelvic inflammatory disease › parametritis

Related subtypes (3): salpingitis, acute female pelvic peritonitis, Fitz-Hugh-Curtis syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Ceftazidime	Approved (phase 4)
Clindamycin Phosphate	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 0.